Irinotecan plus Carboplatin for Carcinoma of Unknown Primary Site
Author Information
Author(s): Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, Hirakawa A, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y
Primary Institution: National Cancer Center Hospital
Hypothesis
The study aims to evaluate the efficacy and toxicity of combined irinotecan and carboplatin therapy in chemotherapy-naive patients with carcinoma of unknown primary site (CUP).
Conclusion
The combination of irinotecan plus carboplatin was found to be active and reasonably well tolerated in patients with CUP.
Supporting Evidence
- An objective response rate of 41.9% was observed in the study.
- The median time to progression was 4.8 months.
- The median overall survival was 12.2 months.
- 1- and 2-year survival rates were 44% and 27%, respectively.
- The most frequent severe adverse events included neutropaenia and anaemia.
Takeaway
Doctors tested a new medicine combination to help patients with a type of cancer where they can't find the original tumor, and it worked pretty well.
Methodology
This phase II study involved administering irinotecan and carboplatin to chemotherapy-naive patients with CUP, with evaluations for efficacy and toxicity.
Potential Biases
The patient population may not represent all CUP patients, as those with poor prognostic features were excluded.
Limitations
The study may have potential bias due to the patient selection and the lack of a control group.
Participant Demographics
The median age of participants was 59 years, with a range from 36 to 78 years, and included both male and female patients.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI, 27.0–57.9%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website